Literature DB >> 11163464

Prevention of acute otitis media by prophylaxis and treatment of influenza virus infections.

W P Glezen1.   

Abstract

Human experimental challenge studies with influenza virus infection and controlled intervention trials have demonstrated beyond doubt the role of influenza virus infection in the pathogenesis of acute otitis media. Influenza virus infections not only disrupt eustachian tube function, but also impair recovery from infection and facilitate attachment of bacterial pathogens to respiratory epithelial cells. Immunization of young children with either inactivated or live, attenuated influenza vaccine will significantly reduce the incidence of acute otitis media. Early treatment of influenza with antiviral medication will reduce eustachian tube dysfunction that results from influenza virus infection. Influenza produces high morbidity in children that could be averted by universal immunization with attenuated nasal spray vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11163464     DOI: 10.1016/s0264-410x(00)00279-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Respiratory illness associated with influenza and respiratory syncytial virus infection.

Authors:  D M Fleming; R S Pannell; A J Elliot; K W Cross
Journal:  Arch Dis Child       Date:  2005-04-26       Impact factor: 3.791

Review 2.  Acute otitis media in children: association with day care centers--antibacterial resistance, treatment, and prevention.

Authors:  David Greenberg; Sigalit Hoffman; Eugene Leibovitz; Ron Dagan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 3.  Control of influenza.

Authors:  W Paul Glezen
Journal:  Tex Heart Inst J       Date:  2004

4.  Impact of A/H1N1 influenza in children at a Brazilian University Hospital.

Authors:  Gabriela Fontanella Biondo; João Carlos Santana; Patrícia M Lago; Jefferson Piva; Paulo Ricardo A Souza; Joana Genz Gaulke; Juliana M Sebben
Journal:  Braz J Infect Dis       Date:  2018-06-05       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.